LoginRegister

    Rusan Pharma gets DCGI nod to APOSAN for treating Parkinsons Disease

    Farhat NasimWritten by Farhat Nasim   |  
    Rusan Pharma gets DCGI nod to APOSAN for treating Parkinsons Disease


    Rusan Pharma said it has developed the drug, which would be available in the form of injections, pen and continuous infusion pumps, indigenously and has received approval from the Drug Controller General of India (DCGI).


    New Delhi: Drug maker Rusan Pharma recently said it has launched a drug to treat Parkinson's disease. The drug -- Aposan -- is used to treat motor fluctuations in patients with Parkinson's Disease which are not sufficiently controlled by oral medications currently available in the country.


    The company said it has developed the drug, which would be available in the form of injections, pen and continuous infusion pumps, indigenously and has received approval from the Drug Controller General of India (DCGI).



    "The company has always put forward indigenously developed high technology advanced delivery products in the Indian market," Rusan Pharma MD Kunal Saxena said in a statement.

    The company wants to ensure that the treatment is affordable and accessible to all Parkinson's disease patients, he added.





    AposanDCGIdrugDrugs Controller General Indiaindian drug marketIndian marketinfusion pumpsInjectionkunal saxenaLaunchmedicinenodParkinson'sParkinson's diseasepenspharmapharmaceuticalRusan Pharma
    Source : With input

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X